Analyzing Beyondspring (BYSI) and Its Competitors
Beyondspring (NASDAQ: BYSI) is one of 188 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its rivals? We will compare Beyondspring to similar companies based on the strength of its earnings, risk, institutional ownership, analyst recommendations, valuation, dividends and profitability.
Institutional and Insider Ownership
1.2% of Beyondspring shares are owned by institutional investors. Comparatively, 47.5% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 14.5% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
This is a breakdown of current ratings and target prices for Beyondspring and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Beyondspring presently has a consensus target price of $54.50, indicating a potential upside of 68.11%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 13.00%. Given Beyondspring’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Beyondspring is more favorable than its rivals.
Earnings and Valuation
This table compares Beyondspring and its rivals revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Beyondspring Competitors||$217.29 million||-$39.39 million||-60.98|
Beyondspring’s rivals have higher revenue, but lower earnings than Beyondspring.
This table compares Beyondspring and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Beyondspring beats its rivals on 7 of the 11 factors compared.
BeyondSpring Inc. is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). Plinabulin has also entered in a Phase I/II clinical trials to investigate its therapeutic potential in combination with the immuno-oncology agent nivolumab. The Company’s BPI-002 program is based on an oral small molecule agent, which induces T-cell activation. The Company’s IkappaB kinase (IKK) program, BPI-003, is based on a small molecule inhibitor of IKK, a protein kinase.
Receive News & Ratings for Beyondspring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyondspring and related companies with MarketBeat.com's FREE daily email newsletter.